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Advanced glycation end products 
(AGEs) promote melanogenesis 
through receptor for AGEs
Eun Jung Lee, Ji Young Kim & Sang Ho Oh
Accumulation of advanced glycation end products (AGEs) is linked with development or aggravation 
of many degenerative processes or disorders, including aging and atherosclerosis. AGEs production in 
skin cells is known to promote stiffness and loss of elasticity through their buildup in connective tissue. 
However, the impact of AGEs has yet to be fully explored in melanocytes. In this study, we confirmed 
the existence of receptor for AGE (RAGE) in melanocytes in western blot and immunofluorescence 
along with increased melanin production in ex vivo skin organ culture and in vitro melanocyte culture 
following AGEs treatment. Cyclic AMP response element-binding protein (CREB) and extracellular 
signal-regulated kinases (ERK) 1/2 are considered as key regulatory proteins in AGEs-induced 
melanogenesis. In addition, blockage experiment using anti-RAGE blocking antibody has indicated 
that RAGE plays a pivotal role in AGE-mediated melanogenesis. Therefore, it is apparent that AGEs, 
known markers of aging, promote melanogenesis via RAGE. In addition, AGEs could be implicated in 
pigmentation associated with photoaging according to the results of increased secretion of AGEs from 
keratinocytes following UV irradiation. AGE-mediated melanogenesis may thus hold promise as a novel 
mean of altering skin pigmentation.
Advanced glycation end products (AGEs) are generated via the Maillard reaction (i.e., nonenzymatic glycation/
oxidation of proteins, lipids, and nucleic acids, which are covalently bonded to reducing sugars)1. Various struc-
tures of AGEs such as Nε -(carboxymethyl)-lysine (CML), pyrraline, pentosidine, or other crossslines2 are known 
to be associated with degenerative process or disorders, including aging3, diabetes, atherosclerosis4, Alzheimer’s 
disease5, and renal failure6. AGEs also implicated in skin aging, accumulate a result of UV irradiation7 in both 
senescent and photoaged skin8,9.
A variety of cutaneous cells, such as fibroblasts and keratinocytes10,11, produce AGEs, which are common 
affiliates of fibronectin, laminin, collagen, elastin8,12, and epidermis13. Accumulated AGEs in collagen and elastin 
of connective tissue lead to stiffening and loss of elasticity14. Furthermore, previous literatures have reported that 
UV-induced intracellular buildup of AGEs generates reactive oxygen species (ROS) damaging dermal proteins 
and triggering inflammatory signaling response. All of these factors attest to the putative influence of AGEs on 
the photoaging of skin such as wrinkling15,16.
UV irradiation, in addition to its role associated with wrinkling, can also clearly intensify skin pigmentation. 
Senile pigmentation (i.e., aged spots or solar lentigo) is another prominent manifestation of chronic actinic 
damage. Considering the already known association of AGEs with skin aging, a correlation between AGEs and 
UV-induced skin pigmentation also seems feasible. Previous studies have confirmed deposition of AGEs in skin 
tissues through immunohistochemical staining and two-dimensional polyacrylamide gel electrophoresis3,17. 
However, it is still uncertain how AGEs exert effects in the course of melanogenesis.
The receptor for advanced glycation end products (RAGE) is a multiligand member of the immunoglobu-
lin superfamily of cell surface receptors that is expressed in various skin cells including fibroblasts, dendritic 
cells, and keratinocytes7. Upon ligand binding, increases in S100/calgranulins, amphoterin, and high mobil-
ity group box 1 (HMGB-1) generate ROS, and proinflammatory upregulation ensues18,19. Earlier studies have 
focused on blockade of RAGE, using anti-RAGE antibody or soluble RAGE (sRAGE) to reduce inflammation20–22 
and demonstrated that RAGE signaling is involved in fibrosis and growth factor secretion21,23 and in matrix 
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metalloproteinase-9 (MMP-9) activation in keratinocytes24. Nevertheless, the impact of AGEs and RAGE binding 
is still unclear in melanogenesis signaling.
In this study, we aimed to investigate the role of AGEs and RAGE in melanin production and examine related 
signaling mechanisms. Our findings provide evidence that AGEs promote melanogenesis through RAGE activa-
tion in melanocytes.
Results
RAGE expression in skin cells. Before performing experiments on the effect of AGEs on melanogenesis, 
we investigated whether melanocytes express RAGE, the known receptor for AGEs. We tested the expression of 
RAGE in primary human dermal fibroblasts (PHDFs) and primary human epidermal keratinocytes (PHEKs) 
together with primary human epidermal melanocytes (PHEMs) using lysates of human endothelial cells (EC) as 
a positive control. Interestingly, PHEMs expressed RAGE as other primary human skin cells and their expressions 
were consistent with previous reports which showed the presence of RAGE in PHDFs and PHEKs7. In addition, 
since we have used mouse melanocyte cell line, melan-a, we checked RAGE expression on melan-a cell as well 
(Fig. 1a). For the confirmation of RAGE expression in melanocytes, we checked RAGE expression in PHEMs and 
skin tissues using melan-A antibody, a melanocyte marker via double immunofluorescence staining. We were 
Figure 1. RAGE expression in skin cells. (a) RAGE protein expression was confirmed by western blot analysis. 
RAGE is expressed in skin cells, PHDF, PHEK, PHEM, and melan-a cell line. Human endothelial cells (EC) 
were used as positive control. (b) Immunofluorescence staining of RAGE in PHEM and (c) human skin tissue 
was performed. Melan-A (red) and RAGE (green) immunostained melanocytes were visualized in the basal 
layer of epidermis. Arrows indicate RAGE-expressing melanocytes. Scale bar represents 20 μ m.
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able to observe melanocytes which stained with melan-A also expressed RAGE in vitro cell (Fig. 1b) and in vivo 
tissue (Fig. 1c). From these results, we found that RAGE expression is indeed present in melanocytes.
AGEs promote epidermal pigmentation in organ-cultured human skin. AGE-mediated melano-
genesis was explored in ex vivo experiments using human skin. AGEs (200 μ g/ml) were delivered twice (day 1 and 3) 
over a period of 5 days to an organ culture system which utilized remnants of breast skin from plastic surgery. 
As a result, increased melanin content was demonstrated (via Fontana-Masson staining) in skin cultures 5 days 
after AGE exposure (Fig. 2a). In AGE-exposed human skin (vs. non-exposed controls), the ratio of pigmented 
epidermal area to total epidermal areas was significantly greater (0.394 ± 0.017 versus 0.593 ± 0.047, * * p < 0.01) 
(Fig. 2b). However, there was no difference in the number of epidermal melanocytes between both control and 
AGEs-delivered tissues (Fig. S1). Taken together, these results indicate that AGEs has stimulatory effect on pig-
mentation without increasing number of epidermal melanocytes.
AGEs induce melanin production and increase expression of melanogenesis-associated mole-
cules in melan-a cells. The melanogenic effect of AGEs was assessed in melan-a cells after first evaluating 
the impact of AGEs on cell viability. No cytotoxicity resulted from preliminary AGEs in bovine serum albu-
min (AGE-BSA), exposure for 4 days (Fig. S2) and AGEs treatment did not induce direct effect on melanocytes 
based on the results of ROS, cytokine (IL-6, TNF-α ) and p38 response (Fig. S3). As cells were exposed to AGEs 
(200 μ g/ml), expression levels of microphthalmia-associated transcription factor (MITF) and tyrosinase, the 
melanogenesis-associated molecules, were increased (Fig. 3a,b). In addition, tyrosinase enzymatic activity rose 
significantly upon incubation with AGEs (Fig. 3c), along with a significant increase in melanin content (~17%) 
compared to control cells (Fig. 3d, * p < 0.05; * * p < 0.01). To see the effect of long incubation of AGEs on melano-
genesis, we treated AGEs on melan-a cells for 2 weeks. Two week-incubation of AGEs augmented more melanin 
contents (~23.9%) in comparison to 4 day-incubation (Fig. S4).
Figure 2. AGEs promote epidermal pigmentation in organ-cultured human skin. (a) Human skin cultures 
exposed to AGEs (200 μ g/ml) twice (Day 1 and 3) in a 5-day period were stained for melanin (Fontana-Masson 
kit) as described by the manufacturer. Pigmentation increased in test samples compared with controls. Right 
column images are enlarged version of left panel. (b) Ratios of pigmented epidermal areas to total epidermal 
areas differed significantly in AGE-exposed and control skin sections, as show in bar graph. Scale bar represents 
100 μ m. * * p < 0.01. All values expressed as mean ± SD of three independent experiments.
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AGEs induce melanin production and increase expression of melanogenesis-associated mole-
cules in PHEMs. Melanogenesis signaling in PHEMs was also investigated. Treatment of AGEs on PHEMs 
resulted in increased protein levels of MITF (Fig. 4a) and tyrosinase (Fig. 4b), compared with control samples. 
Moreover, AGEs exposure in PHEMs promoted the increase of tyrosinase enzymatic activity (Fig. 4c) and mel-
anin content (~24.4%) (Fig. 4d). The effect of longer incubation of AGEs on melanogenesis was observed in 
PHEMs as well. Longer incubation with AGEs (2 weeks) augmented melanin production up to ~28.5% (Fig. S4). 
Moreover, the increase in melanin production through AGEs was also observed in PHEMs from non-genital skin. 
(Fig. S5). These results confirm that melanogenesis singaling is activated by AGEs treatment in PHEMs along 
with melan-a cells.
AGEs upregulate RAGE expression and its downstream signaling. The level of RAGE in cells treated 
with AGEs was investigated. The upregulation of RAGE mRNA (Fig. 5a) and protein expression (Fig. 5b) was 
observed in cells with AGEs exposure. Downstream targets of RAGE signaling, ERK and CREB activation were 
evaluated to determine their relationship in AGE-mediated melanogenesis. Relative to controls, protein levels 
of p-ERK (Fig. 5c) and p-CREB (Fig. 5d) (phosphorylated states) were significantly increased by AGEs exposure 
in PHEMs. ERK and CREB phosphorylation was also detected in AGEs-treated melan-a cell line (Fig. 5e,f) Taken 
together, these results demonstrate that AGEs stimulate RAGE pathway by increasing RAGE expression and 
phosporylating ERK and CREB.
Functional significance of RAGE in AGE-mediated melanogenesis. We subsequently investigated 
whether the receptor for AGE (RAGE) participates in AGE-induced melanogenesis. To investigate the role of 
Figure 3. AGEs induce melanin production and increase expression of melanogenesis-associated 
molecules in melan-a cells. Media of melan-a cells were changed to serum free media and AGEs (200 μ g/ml) 
were treated. (a) MITF levels were assayed after 4 h AGEs exposure. (b) Tyrosinase expression and (c) its activity 
were confirmed at Day 3 by western blot analysis and zymography, respectively. (d) Melanin content exposed 
to AGEs for 4 days was measured. * p < 0.05; * * p < 0.01. All data expressed as mean ± SD of three independent 
experiments.
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RAGE in AGE-mediated melanogenesis, cells that had been preincubated (1 h) in RAGE blocking antibody (R&D 
Systems)25 were tested for p-CREB and MITF expression after incubation with AGEs (200 μ g/ml). The expected 
rise in expression of p-CREB and MITF (due to AGEs) was abrogated by prior RAGE blockade (Fig. 6a,b). 
Likewise, tyrosinase activity (Fig. 6c) and melanin synthesis (Fig. 6d) did not increase. These findings suggest that 
AGE-mediated melanogenesis relies on RAGE signaling.
Discussion
Previous studies of AGEs have largely focused on related systemic processes or diseases, such as aging and 
diabetes14,26–29. AGEs have been found to accumulate in the blood vessels of diabetic patients, leading to excessive 
ROS production and quenching of nitric oxide activity in vessels14,30,31. In skin components, such as fibronec-
tin, laminin, elastin, and collagen, accumulation of AGEs take the form of Nε -(carboxymethyl)-lysine (CML), 
pyrraline, pentosidine, or other molecules2 as consequences of aging and actinic damage. AGEs accumulation 
is fundamental in skin aging, as it leads to oxidative stress and inflammation16,17,32. High levels of AGEs likewise 
may impair dermal regeneration, reducing collagen solubility due to intermolecular crosslinking and matrix met-
alloproteinase resistance7,33,34. However, aside from the known contribution of AGEs to the wrinkling of aging 
skin, the interrelationship of AGEs and melanocytes has not been adequately studied.
Skin pigmentation is a frontline barrier to damage by internal and external stressors such as variable hor-
mones and UV exposure35, and in conjunction with wrinkles, it is considered as a hallmark of photoaging. Since 
repeated UV exposure is a culprit of pigmentary changes and skin cancers36,37, mechanisms of UV damage and 
protective strategies have already been extensively researched38. UV irradiation induces oxidative stress, boosts 
proinflammatory cytokines and generates harmful AGEs in skin17,39. In addition, as skin is exposed to UV, 
melanocortin-1 receptor (MC1R) and its ligand, α -melanocyte-stimulating hormone (α -MSH) and adrenocor-
ticotropic hormone (ACTH), are particularly responsive to stresses. The signal pathway through MC1R is critical 
in driving melanin synthesis40 by increasing intracellular cAMP levels41 and activating protein kinase A42. In our 
Figure 4. AGEs induce melanin production and increase expression of melanogenesis-associated 
molecules in primary human epidermal melanocytes. AGEs (200 μ g/ml) were treated to PHEMs in serum 
free media. (a) After 4 h incubation, MITF levels were confirmed. (b) Tyrosinase expression and (c) activity 
were assayed at Day 2. (d) At Day 3, melanin content exposed to AGEs was measured. * p < 0.05. All data 
expressed as the mean ± SD of three independent experiments.
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study, we investigated the contribution of AGEs-RAGE to pigmentation as an alternate mechanism of pigmenta-
tion signaling other than MC1R-mediated pathway and further sought to oberve the implication of AGEs-RAGE 
pathway in UV-induced pigmentation. And through our experiments, we were able to identify the expression of 
RAGE in melanocytes and the role of AGEs in melanogenesis. In order to support the possibility of the AGEs’ 
role in UV-induced pigmentation, we checked AGEs secretion and production from supernatant and lysates of 
keratinocytes after UV irradiation. Consequently, increased secretion and production of AGEs were observed 
from keratinocytes flollowing UV irradiation (Fig. S6).
In this study, a commercially available mixture of Nε -(carboxymethyl)-lysine, pentosidine, and others43, was 
used for seeing the effects of AGEs on melanogenesis in ex vivo skin organ culture and in vitro melanocyte culture. 
Incubation with AGEs at the concentration of 200 μ g/ml had no detrimental effect on cell viability and did not 
show any increase in ROS and proinflammatory cytokines such as IL-6 and TNF-α . In addition, AGEs appeared 
to have no direct stress effect on melanocytes when phosphorylated p38 expression was checked. However, AGEs 
did heighten melanin production, tyrosinase activity, and the expression of melanogenesis-associated molecules 
including MITF and tyrosinase. Additionally, sections of cultured human skin (by Fontana-Masson stain) showed 
proportionately higher melanin pigmentation by after AGEs exposure, based on ratios of pigmented epidermal 
areas to total epidermal areas (test samples vs. controls). The above results may indicate that AGEs could influ-
ence melanogenesis even at the concentration of AGEs, that does not affect ROS and proinflammatory cytokine 
production.
AGE-mediated signaling is initiated once the corresponding receptor for AGE (RAGE) is activated44. RAGE 
is expressed in various kinds of cells such as astrocytes, malignant glioma, endothelial cells, and fibroblasts7,45. 
Figure 5. AGEs upregulate RAGE expression and its downstream signaling. (a) PHEMs were treated with 
AGEs (200 μ g/ml) for 2 h in serum free media and RAGE mRNA expression was determined by realtime PCR. 
(b) RAGE protein levels were assayed after 4 h AGEs incubation. In PHEMs, (c) p-ERK1/2 and (d) p-CREB 
protein levels were determined after exposure to AGEs (200 μ g/ml) in serum free media for 15 min and 30 min, 
respectively. In melan-a cells, protein levels of (e) p-ERK1/2 and (f) p-CREB were also measured. * p < 0.05. All 
data expressed as the mean ± SD of three independent experiments.
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To date, the details of RAGE expression in melanocytes have been unclear, but our study proved the existence of 
RAGE expression in melanocytes through western blot and immunofluorescence studies, suggesting its possible 
role in melanocytes. Melanogenesis through AGEs-RAGE pathway, which is confirmed by RAGE blockage exper-
iments, is a new characterization of RAGE functions since RAGE is known to be involved in inflammation, cell 
migration, and ROS production. Thus, RAGE could be a crucial factor in melanogenesis through AGEs.
AGE-RAGE interaction is, in fact, associated with several signaling pathways, namely ERK1/2, phosphatidyl- 
inositol 3 kinase, Cdc42/Rac, and stress-activated protein kinase/c-Jun-NH2-terminal kinase (SAPK/JNK)34,46. 
Huttunen et al. have demonstrated that RAGE signaling also stimulates CREB phosphorylation (and ERK1/2 
activation thereby) in separate neuroblastoma and embryonic stem cell lines47. On this basis, we explored the 
possibility that CREB phosphorylation, as a reputed feature of major MC1R-mediated melanogenic signaling41, 
might similarly be involved in melanocytic RAGE signaling. As p-CREB binds to the CRE consensus motif of 
MITF, expression levels of MITF and tyrosinase increase accordingly48–50. Following the exposure of melanocytes 
to AGEs, we detected increased phosphorylation of ERK (p-ERK) and CREB (p-CREB), which are downstream 
targets of RAGE signaling51. In addition, increased p-CREB expression and melanogenesis-associated signaling, 
Figure 6. Functional significance of RAGE in AGE-mediated melanogenesis. To block AGE-RAGE 
interaction, PHEMs exposed (1 h) to anti-RAGE antibody (20 μ g/ml) were incubated with AGEs (200 μ g/ml) 
in serum free media. After 30 min, 4 h, 48 h, and 72 h, (a) p-CREB, (b) MITF expression, (c) tyrosinase activity, 
and (d) melanin content, respectively were assessed. * p < 0.05. All data expressed as the mean ± SD of three 
independent experiments.
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including MITF expression, tyrosinase activity, and melanin production, in AGE-exposed cells were ablated 
through preincubation in anti-RAGE antibody, suggesting that CREB and pigmentation signaling due to AGEs 
are achieved via RAGE. Therefore, AGE-RAGE interaction may induce both ERK and CREB signaling, increase 
MITF expression and tyrosinase activity and ultimately boost melanin production in melanocytes.
In conclusion, our findings indicate that AGEs, secreted by keratinocytes in response to UV irradiation, are 
capable of stimulating melanogenesis through ERK and CREB signaling via RAGE. Moreover, RAGE plays a 
regulatory role in melanogenesis, rather than engaging in free radical production and proinflammatory cas-
cades as previously asserted. Our discovery that AGE-RAGE interaction upregulates melanogensis through 
CREB-MITF-tyrosinase pathway in melanocytes illuminates a novel mechanism of melanogenesis. Although still 
in early stages of research, AGEs and RAGE signaling may be a promising target in preventing the melanogenesis 
accompanying photoaging
Materials and Methods
Cell cultures. Human foreskin samples were obtained after written informed consent and in accordance with 
a protocol approved by Yonsei University College of Medicine Institutional Review Board. PHEKs, PHEMs, and 
PHDFs were isolated from foreskin samples and maintained in keratinocyte basal medium (KBM) with all sup-
plements (Lonza, Walkersville, MD, USA), melanocyte basal medium (MBM) with all supplements plus 200 nM 
2-O-tetradecanoyl-phorbor-13-acetate (TPA; Sigma-Aldrich, St. Louis, MO, USA), and Dulbecco’s modified 
Eagle’s minimal essential medium (DMEM; Welgene, Daegu, Republic of Korea) supplemented with 10% fetal 
bovine serum (FBS; Welgene) and 1% penicillin-streptomycin (Welgene), respectively. For experiments, PHEKs, 
PHEMs, PHDFs were used at passage number between 3 and 5. Cells from 3 different donors with age of 10–13 
were used in this study. The non-tumorigenic melan-a cell line of mouse melanocytes, gifted by Prof. Dorothy C. 
Bennett at St George’s Hospital Medical School, London, UK, was cultured in RPMI 1640 medium (Welgene), 
which contains 10% FBS, 1% penicillin-streptomycin, and 200 nM TPA. HaCaT cells, an immortalized human 
keratinocyte cell line, were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. All 
cells were maintained at 37 °C in a humidified 5% CO2 incubator.
Reagents. AGE-BSA (Calbiochem, Darmstadt, Germany), which is a mix of Nε -(carboxymethyl)-lysine, 
pentosidine, and others, were used throughout this study. BSA was purchased from Sigma-Aldrich. For blocking 
RAGE, anti-RAGE antibody was from R&D Systems (Abingdon, UK).
Western blot analysis. Whole cell extracts were lysed in RIPA buffer. Proteins were resolved by 10% 
SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, which were blocked by 5% 
skim milk in TBST and incubated with primary antibodies against MITF (Abcam, Cambridge, UK), tyrosinase 
(Santa Cruz Biotechnology, Dallas, TX, USA), p-CREB, CREB, p-ERK1/2, ERK1/2 (Cell Signaling Technology, 
Danvers, MA, USA), RAGE (Abcam), or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Santa Cruz 
Biotechnology) at 4 °C overnight. Appropriate secondary antibodies were added, and the protein bands were 
detected using an enhanced chemiluminescence reagent. Test blots were probed for test proteins and GAPDH in 
the same blot.
Confocal microscopy. Melanocytes were washed in phosphate-buffered saline (PBS) and fixed in 4% par-
aformaldehyde (room temperature, 15 minutes). Samples were then washed in PBST (PBS + 0.1% Tween-20) 
three times and incubated overnight (4 °C) in anti-RAGE (R&D Systems) and anti-Melan-A (Leica Biosystems, 
Newcastle, UK). For human skin tissues, formalin fixed paraffin-embedded tissue sections were prepared for 
immunofluorescent staining. Skin tissues were incubated with anti-RAGE and Melan-A. All samples were 
mounted in a solution of 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc., Burlingame, CA, 
USA). Slides were evaluated with confocal microscopy (LSM 700; Carl Zeiss, Oberkochen, Germany).
Skin organ culture. Postsurgical remnants of human breast skin were obtained after written informed con-
sent and in accordance with protocol approved by Yonsei University College of Medicine Institutional Review 
Board and prepared as previously described52,53. Samples were immersed in DMEM with 10% FBS and 1% pen-
icillin/streptomycin. AGEs (200 μ g/ml) were added twice (Day 1 and 3) during the 5-day incubation (37 °C, 5% 
CO2). Frozen tissue sections were then subjected to Fontana-Masson staining for melanin (Abcam kit). Melanin 
positive epidermal areas relative to total epidermal areas were measured by using Image J software (National 
Institutes of Health, Bethesda, MD, USA) based on previously reported protocols54,55. In brief, TIFF image files 
were opened in Image J and were adjusted to red, green and blue (RGB) color space in color threshold section. 
Total epidermal area was measured by analyze section in program. By defining minimum and maximum vales 
for each RGB color, positive areas of Fontana-Masson staining were displayed. Then, positive staining area was 
measured. We calculated the ratio of pigmented epidermal area (PA, Fontana Masson positive area)-to-total epi-
dermal area (EA, total epidermal area).
Melanin content. To assess the melanin production, melan-a cells and PHEMs were exposed to AGEs (200 μ g/ml) 
or BSA for 4 days. The cell pellets were then incubated in 1 N NaOH (60 °C, 2 h). Absorbance at 405 nm (detected 
by ELISA reader) was compared with synthetic melanin standard curve (Sigma-Aldrich).
Tyrosinase activity assay. Measurements of tyrosinase activity were performed in accordance with a pre-
viously reported method56. In brief, the cells were incubated (72 h) in AGEs (200 μ g/ml) or BSA and lysed in 
radioimmunoprecipitation assay (RIPA) buffer. Tris-glycine sodium dodecyl sulfate (SDS) sample buffer with-
out mercaptoethanol was added to lysed samples and then was resolved through 10% SDS-polyacrylamide gel 
electrophoresis. The gels were immersed in 0.1 M NaH2PO4 (pH 6.8, 30 min) and then buffer was replaced. After 
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rinsing, a buffer with 5 mM L-DOPA (Sigma-Aldrich) was added to the gels and incubated (37 °C, 3 h) before 
visualizing the darkened electrophoretic bands.
Real-time PCR. Total RNA was isolated from primary human epidermal melanocytes using RNeasy Plus 
Mini Kit (QIAGEN, Valencia, CA, USA). cDNA was synthesized using PrimeScript 1st strand cDNA Synthesis 
Kit (Takara Bio, Otsu, Shiga, Japan) following the manufacturer’s protocol. Quantitative real-time PCR was per-
formed using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The primers for 
PCR were as follows: RAGE 5′-GTG TCC TTC CCA ACG GCT C-3′ (forward) and 5′-ATT GCC TGG CAC 
CGG AAA A-3′ (reverse); GAPDH 5′-AAG GTG AAG GTC GGA GTC AAC-3′ (forward) and 5′-GGG GTC 
ATT GAT GGC AAC AAT A-3′ (reverse); IL-6 5′-TAG TCC TTC CTA CCC CAA TTT CC-3′ (forward) and 
5′-TTG GTC CTT AGC CAC TCC TTC-3′ (reverse); TNF-α 5′-CTG AAC TTC GGG GTG ATC GG-3′ (for-
ward) and 5′-GGC TTG TCA CTC GAA TTT TGA GA-3′ (reverse); β -actin 5′-GGC TGT ATT CCC CTC CAT 
CG-3′ (forward) and 5′-CCA GTT GGT AAC AAT GCC ATG T-3′ (reverse).
Cytotoxicity assay. To check cell viability, the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay (Sigma-Aldrich) was used. PHEMs and melan-a cells were incubated in differing concentrations 
of AGEs or BSA for 4 days. All cells in a 96-well plate were incubated with MTT stock solution (37 °C, 4 h). After 
labeling with MTT, the cells were incubated (10 min) in dimethyl sulfoxide (DMSO; Sigma-Aldrich), and absorb-
ance of each sample was read at 570 nm.
Cellular ROS measurement. To detect the production of ROS within the cells, flow cytometry was per-
formed with LSRII (BD Biosciences, North Ryde, New South Wales, Australia). 20,70-dichlorofluorescein diac-
etate (H2-DCFDA; Molecular Probes, Eugene, OR, USA) was used. ROS production was compared between 
control, BSA and AGEs treated melan-a cells. H2O2 incubated cells were used as positive control. Data were 
analyzed using FlowJo (TreeStar, San Carlos, CA, USA).
UVB irradiation. A Spectronics BLE-1T158 lamp (Spectronics Corp., Westbury, NY, USA) served as a UVB 
source. Keratinocytes were irradiated with 50 mJcm−2 UVB at room temperature.
Statistical analysis. All values were expressed as means ± SD. Student’s t-test was used between two 
groups and ANOVA analysis was used for comparing multiple groups, with statistical significance set at p < 0.05. 
Standard software (SPSS; SPSS Inc., Chicago, IL, USA) was employed.
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